Objective: Tacrolimus is an immunosuppressive drug with a narrow therapeutic range and
wide interindividual variation in its pharmacokinetics. Cytochrome P450 (CYP) 3A and P …

Objective The immunosuppressive drug tacrolimus requires strict therapeutic monitoring due
to its narrow therapeutic index and great inter-individual variability. Cytochrome P450 3A4 …

Background. A body-weight-based dose of tacrolimus often results in marked individual
diversity of blood drug concentration. Tacrolimus is a substrate for cytochrome P450 (CYP) …

The impact of CYP3A and MDR1 gene single‐nucleotide polymorphisms on long‐term
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …

The aims of this study were to investigate the influence of CYP3A5 and MDR1 genetic
polymorphisms on tacrolimus pharmacokinetics in Chinese renal transplant recipients, so as …

Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …

Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …

Previously, we reported that, at 3 months after renal transplantation, individuals with
CYP3AP1 genotype CYP3AP1* 1 (linked to CYP3A5* 1 and strongly associated with …

We retrospectively examined the association of polymorphisms in the CYP3A, CYP2J2,
CYP2C8, and ABCB1 genes with pharmacokinetic (PKs) and pharmacodynamic (PDs) …

OBJECTIVE: The objective of this study was to assess the influence of CYP3A5 and MDR1
genetic polymorphisms on tacrolimus pharmacokinetics in Japanese renal transplant …